Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04789096
Title Tucatinib Together With Pembrolizumab and Trastuzumab (TUGETHER)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Breast Cancer Trials, Australia and New Zealand

Her2-receptor positive breast cancer


Pembrolizumab + Trastuzumab + Tucatinib

Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib

Age Groups: adult | senior
Covered Countries

No variant requirements are available.